Abstract
Advances in the treatment of demented individuals is critically dependent upon experimental administration of new drugs to such people, who, by definition, frequently cannot provide informed consent. Ethical problems associated with studies on demented individuals are therefore of great importance. While there is some similarity to other groups (children, psychotic individuals and patients in coma) there also exist several differences. Obtaining an informed consent from a dementing individual is always problematic. Advance directives are helpful to caregivers and patients should be encouraged, at early stages of the disease, to provide them. Participation in drug studies carries inherent benefits to patients, but at the same time exposes them to risks and discomforts which should be monitored and reviewed more intensively than in studies on cognitively intact individuals. The vulnerability of demented people and their dependence requires special attention by the institutional review board (IRB), unique items to be included in the study protocols and consent forms, etc. Representatives of patients advocacy groups can make important contributions to the IRB, to serve the best interests of the patient and prevent exploitation by the industry as well as by researchers, and honoring the autonomy of the patients. It would be helpful and justified to enable subjects to continue in the study in an open-label design in this situation, once they sign a suitable informed consent. A no-fault insurance could be provided to the patient in this situation.
Keywords: Caregivers, institutional review board, controlled drug trial, dementing people
Current Alzheimer Research
Title: Drug Trials in Dementia: Challenging Ethical Dilemmas
Volume: 4 Issue: 4
Author(s): Amos D. Korczyn
Affiliation:
Keywords: Caregivers, institutional review board, controlled drug trial, dementing people
Abstract: Advances in the treatment of demented individuals is critically dependent upon experimental administration of new drugs to such people, who, by definition, frequently cannot provide informed consent. Ethical problems associated with studies on demented individuals are therefore of great importance. While there is some similarity to other groups (children, psychotic individuals and patients in coma) there also exist several differences. Obtaining an informed consent from a dementing individual is always problematic. Advance directives are helpful to caregivers and patients should be encouraged, at early stages of the disease, to provide them. Participation in drug studies carries inherent benefits to patients, but at the same time exposes them to risks and discomforts which should be monitored and reviewed more intensively than in studies on cognitively intact individuals. The vulnerability of demented people and their dependence requires special attention by the institutional review board (IRB), unique items to be included in the study protocols and consent forms, etc. Representatives of patients advocacy groups can make important contributions to the IRB, to serve the best interests of the patient and prevent exploitation by the industry as well as by researchers, and honoring the autonomy of the patients. It would be helpful and justified to enable subjects to continue in the study in an open-label design in this situation, once they sign a suitable informed consent. A no-fault insurance could be provided to the patient in this situation.
Export Options
About this article
Cite this article as:
Korczyn D. Amos, Drug Trials in Dementia: Challenging Ethical Dilemmas, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788909
DOI https://dx.doi.org/10.2174/156720507781788909 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis
Current Drug Targets - CNS & Neurological Disorders Neurotoxicity of Insecticides
Current Medicinal Chemistry Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease
Current Proteomics Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
Current Medicinal Chemistry Positron Emission Tomography in Neuroimaging - An Update
Current Medical Imaging Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Amyloid Formation in Surfactants and Alcohols: Membrane Mimetics or Structural Switchers?
Current Protein & Peptide Science Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets The Importance of Stereochemistry on the Actions of Vitamin D
Current Topics in Medicinal Chemistry Conference Report: The American Association for the Advancement of Science (AAAS), 180th Annual Meeting Chicago, IL, USA Feb 13-17, 2014 “Meeting Global Challenges: Discoveries & Innovation”
CNS & Neurological Disorders - Drug Targets Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Lack of Association Between SLC24A4 Polymorphism and Late-onset Alzheimer's Disease in Han Chinese
Current Neurovascular Research Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance
Current Neurovascular Research